Sep 16, 2026 08:00AM
Sep 16, 2026 08:00AM
Aug 20, 2026 08:00AM
Aug 20, 2026 08:00AM
Aug 18, 2026 08:01AM
Aug 18, 2026 08:00AM
Aug 4, 2026 08:01AM Alzamend Neuro raises $7.5M in Series D preferred stock deal
Aug 4, 2026 08:00AM
Apr 7, 2026 08:00AM
Mar 26, 2026 08:02AM
Mar 26, 2026 08:00AM
Mar 16, 2026 08:02AM
Mar 16, 2026 08:00AM
Nov 19, 2025 08:01AM Alzamend Neuro completes Phase II clinical trial of AL001 lithium therapy
Nov 19, 2025 08:00AM
Jul 28, 2025 08:00AM
Jul 23, 2025 08:00AM
Jun 16, 2025 08:00AM
May 29, 2025 08:04AM
May 29, 2025 08:00AM
May 19, 2025 08:03AM Alzamend Neuro (ALZN) Enrolls First Patient in its Phase II Clinical Trial of AL001 “Lithium in Brain” Study
May 19, 2025 08:00AM
May 13, 2025 08:00AM
May 8, 2025 08:01AM
May 8, 2025 08:00AM
May 7, 2025 08:00AM
Mar 25, 2025 08:00AM
Mar 18, 2025 08:00AM Alzamend Neuro Announces Initiation Date of Phase II Clinical Trial of AL001 for Treatment of Major Depressive Disorder to take Place at Massachusetts General Hospital
Mar 11, 2025 08:00AM
Mar 4, 2025 08:11AM
Mar 4, 2025 08:10AM
Feb 25, 2025 08:00AM
Feb 19, 2025 08:04AM
Feb 19, 2025 08:00AM
Jan 15, 2025 08:00AM Alzamend Neuro to Present at the Sequire Investor Summit
Dec 18, 2024 08:00AM
Dec 12, 2024 08:00AM
Nov 19, 2024 08:02AM
Nov 19, 2024 08:00AM
Oct 16, 2024 08:06AM
Oct 16, 2024 08:00AM
Oct 15, 2024 08:04AM Alzamend Neuro (ALZN) Regains Compliance with Nasdaq Listing Standards
Oct 15, 2024 08:00AM
Oct 10, 2024 08:00AM
Aug 26, 2024 08:04AM
Aug 26, 2024 08:00AM
Aug 19, 2024 08:06AM
Aug 19, 2024 08:00AM
Aug 12, 2024 08:03AM Alzamend Neuro (ALZN) Partners with Massachusetts General Hospital for a Phase II Clinical Trial of AL001
Aug 12, 2024 08:00AM

1,232,665 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All